|
|
News Breaks | | | | March 8, 2013 | | 11:04 EDT |  | RGRX | RegeneRx receives notice of allowance for second U.S. heart patent
RegeneRx Biopharmaceuticals announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office claiming compositions and methods for treating, preventing, inhibiting, reducing, or repairing tissue deterioration, injury or damage due to heart failure using Thymosin beta 4, its isoforms and fragments, derivatives and analogs. The patent is projected to expire in July 2026. The company holds similar patents issued recently in the US, EU and China. | |
|
News For RGRX From The Last 14 Days Check below for free stories on RGRX the last two weeks. |
|
|
| There are no results for RGRX |
|
|
|
|
|
|
